Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Britannia Life SciencesBLSIF Return-on-Tangible-Asset is 63.30% as of Mar. 2026, which is 63% above its 10-year median of 38.86. The stock has 5 warning signs investors should review. Among 1,413 Biotechnology companies, Britannia Life Sciences ranks better than 99.29% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Britannia Life Sciences's annualizedNet Income for the quarter that ended in Mar. 2026 was $10.57 Mil. Britannia Life Sciences's average total tangible assets for the quarter that ended in Mar. 2026 was $16.69 Mil. Therefore, Britannia Life Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 63.30%.
The historical rank and industry rank for Britannia Life Sciences's Return-on-Tangible-Asset or its related term are showing as below:
BLSIF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -426.49 Med: 38.86 Max: 101.97
Current: 94.32
During the past 6 years, Britannia Life Sciences's highest Return-on-Tangible-Asset was 101.97%. The lowest was -426.49%. And the median was 38.86%.
BLSIF's Return-on-Tangible-Asset is ranked better than 99.29% of 1413
companies
in the Biotechnology industry
Industry Median: -35.75
vs BLSIF: 94.32
Britannia Life Sciences (OTCPK:BLSIF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Britannia Life Sciences Return-on-Tangible-Asset Related Terms
Britannia Life Sciences Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Britannia Life Sciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Britannia Life Sciences Return-on-Tangible-Asset Chart
BLSIF vs VRTX, REGN, MRNA: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Britannia Life Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Britannia Life Sciences Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Britannia Life Sciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Britannia Life Sciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 63.30% mean?
Britannia Life Sciences (BLSIF) has a Return-on-Tangible-Asset of 63.30% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Britannia Life Sciences and its competitors. This is 63% above median its historical median of 38.86. According to the industry distribution chart, Britannia Life Sciences ranks #10 out of 1413 companies in the Biotechnology industry, placing it in the top 0.7%.
Is Britannia Life Sciences' Return-on-Tangible-Asset too high?
Britannia Life Sciences' current Return-on-Tangible-Asset of 63.30% is 63% above median its 10-year median of 38.86. Based on the distribution chart, Britannia Life Sciences ranks #10 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Britannia Life Sciences' Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Britannia Life Sciences ranks #10 out of 1413 companies for Return-on-Tangible-Asset. This places Britannia Life Sciences in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Britannia Life Sciences and its competitors. Britannia Life Sciences's current Return-on-Tangible-Asset is 63.30%, which is 63% above median its own 10-year median of 38.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Britannia Life Sciences stock overvalued right now?
Britannia Life Sciences (BLSIF) has a current Return-on-Tangible-Asset of 63.30%. The current Return-on-Tangible-Asset is 63.30%, which is 63% above median its 10-year median of 38.86. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Britannia Life Sciences (BLSIF), the current Return-on-Tangible-Asset is 63.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Britannia Life Sciences Inc provides product testing, safety assessment, and manufacturing services to the cosmetic and consumer packaged goods industries in the United Kingdom and globally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLSIF has been successfully added to your 
